Janux Therapeutics (JANX) Total Current Liabilities (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Total Current Liabilities data on file, last reported at $58.9 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $58.9 million, up 236.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $58.9 million (up 236.62% YoY), and the FY2025 annual result was $25.0 million, up 43.18% from the prior year.
• Total Current Liabilities rose to $58.9 million in Q1 2026 per JANX's latest filing, from $25.0 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $58.9 million in Q1 2026 and troughed at $10.6 million in Q1 2024.
• A 5-year average of $19.3 million and a median of $16.5 million in 2022 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2024 and 2026: Total Current Liabilities plunged 35.52% in 2024, then jumped 236.62% in 2026.
• A 5-year view of Total Current Liabilities shows it stood at $16.5 million in 2022, then retreated by 21.05% to $13.0 million in 2023, then soared by 33.96% to $17.5 million in 2024, then soared by 43.18% to $25.0 million in 2025, then surged by 135.69% to $58.9 million in 2026.
• Business Quant data shows JANX's Total Current Liabilities at $58.9 million in Q1 2026, $25.0 million in Q4 2025, and $27.8 million in Q3 2025.